CAR AND TOY CAR

Description

THIS DESIGN RELATES TO A TOY CAR / AUTOMOBILE, WHICH HAS A BODY WHICH COMPRISES: “- A FRONT COMPARTMENT INCLUDING TWO HEADLIGHTS, AND A HOOD; “- A PASSENGER COMPARTMENT DELIMITED BY A WINDSHIELD, TWO SIDE DOORS WITH WINDOWS, AND A ROOF; AND “- A REAR COMPARTMENT, WHICH IS CLOSED BY A REAR DOOR AND INCLUDES TWO REAR LIGHTS. “THE DESIGN IS CHARACTERIZED BY: “- THE HOOD HAS A RECESSED CENTRAL SECTION, THE WHICH IS DIVIDED INTO TWO SUBSECTIONS EMBEDDED BY A MOLDING PLACED ALONG THE In the longitudinal direction, these embedded subsections are placed symmetrically in relation to TO THE MOLDING;“- THE TOY CAR INCLUDES A FRONT STABILIZER THAT IS CONNECTED BY A PILLAR TO A FRONT SECTION OF THE FRONT COMPARTMENT; “- EACH HEADLIGHT IT IS SITUATED IN A CORRESPONDING SLANTED GROOVE WITH RESPECT TO THE LONGITUDINAL DIRECTION, THE TWO SLOTS ARE PLACED SYMMETRICALLY WITH RESPECT TO THE LONGITUDINAL DIRECTION;“- THE PART The front of the toy car also includes two quadrangular front vents. FORMED IN THE CORRESPONDING OPPOSITE REAR SIDE PARTS RAISED FORWARD OF THE SAME FRONT PART AND EXTEND SYMMETRICALLY FROM EACH OTHER WITH RESPECT TO DIRECTION LONGITUDINAL;“- ON THE OUTER SIDE OF EACH FRONT VENT, TWO CORRESPONDING FENDERS They are positioned at the front, both have an upward concavity and are partially HOUSED WITHIN THE FRONT VENT ITSELF;“- AT THE REAR, THE CAR / AUTOMOBILE OF The toy is equipped with two double-profile rear fenders supported by two spoilers. 87 X FOR THE PHOENIX 1 STUDY INVESTIGATORS ET AL: "EFFICACY AND SAFETY OF USTEKINUMAB, A HUMAN INTERLEUKIN-12 / 23 MONOCLONAL ANTIBODY, IN PATIENTS WITH PSORIASIS: 76-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PHOENIX 1)", THE LANCET, LANCET LIMITED. LONDON, GB, VOL. 371, N° 9625, 17 MAY 2008 (2008-05-17), PAGES 1665-1674, XP022666486, ISSN: 0140-6736, DOI: 10.1016 / S0140-6736(08)60725-4 [RETRIEVED ON 2008-05-15] Reivindicaciones afectadas 1, 6-14 Y THE WHOLE DOCUMENT BUT SEE E.G. THE ABSTRACT OR PAGE 1667 Reivindicaciones afectadas 1- 15 X FOR THE PHOENIX 2 STUDY INVESTIGATORS ET AL: "EFFICACY AND SAFETY OF USTEKINUMAB, A HUMAN INTERLEUKIN-12 / 23 MONOCLONAL ANTIBODY, IN PATIENTS WITH PSORIASIS: 52-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PHOENIX 2)", THE LANCET, LANCET LIMITED. LONDON, GB, VOL. 371, N° 9625, 17 MAY 2008 (2008-05-17), PAGES 1675-1684, XP022683389, ISSN: 0140-6736(08)60726-6 [RETRIEVED ON 2008-05-17] Claims affected 1, 6-14 AND THE WHOLE DOCUMENT, BUT SEE EG THE ABSTRACT OR PAGE 1676 Claims affected 1- 15 X DUVALLET EMILIE ET ​​AL: "INTERLEUKIN-23: A KEY CYTOKINE IN INFLAMMATORY DISEASES", ANNALS OF MEDICINE, TAYLOR & FRANCIS AB, SE, VOL. 43, No. 7, NOVEMBER 1, 2011 (2011-11-01), PAGES 503-511, XP009177356, ISSN: 0785-3890. 2011.577093 Claims affected 1-15 AND THE WHOLE DOCUMENT BUT SEE EG THE ABSTRACT Claims affected 1-15 Observations: THIS REPORT WAS BASED ON THE PCT INTERNATIONAL SEARCH REPORT OF THE OFFICE EUROPEAN PATENT REGISTRATION NO. WO 2014 / 149425. Date of report completion: January 22, 2018 Examiner: Corina Turner Andrade 122 A WO 2006 / 058630 A1 (BAYER HEALTHCARE AG [DE]; ROEHRIG SUSANNE [DE] ; POHLMANN JENS [CH]; AR) 8 JUNE 2006 (2006-06-08) THE PRODUCT IN STEP B), THE PRODUCT OF EXAMPLE 10 A THE PRODUCT OF EXAMPLE 11A THE WHOLE DOCUMENT Claims affected 1-23,26 A WO 2013 / 093508 A2 (OSLO UNIVERSITY HOSPITAL HF [NO]; GOLDING LOUISE [GB]) 27 JUNE 2013 (2013-06-27) CITED IN THE APPLICATION THE WHOLE DOCUMENT Affected Claims 1-26 X EP 0 023 045 A1 (AJINOMOTO KK [JP]) JANUARY 28, 1981 (1981-01-28) SEVERAL EXAMPLES Claims affected 24.25 A EP 0 023 045 A1 (AJINOMOTO KK [JP]) JANUARY 28, 1981 (1981-01-28) SEVERAL EXAMPLES Claims affected 1-23,26 X DATABASE PUBCHEM [ONLINE]; NOVEMBER 30, 2012 (2012-11-30), XP002744347, ACCESSION NO. 69228021 DATABASE ACCESSION NO. 69228021 DATABASE ACCESSION NO. 69228021 5,10-DIOXO-1- PHENOXYCARBONYLDIIMIDAZO [1,4-B: 1',4'-E]PYRAZINE-6-CARBOXYLIC ACID Reivindicaciones afectadas 25 A DATABASE PUBCHEM [ONLINE] NIH; 30 NOVEMBER 2012 (2012-11-30), XP002744347, ACCESSION No. 69228021 DATABASE ACCESSION No. 69228021 5,10-DIOXO-1-PHENOXYCARBONYLDIIMIDAZO [1,4-B:1',4'- E]PYRAZINE-6-CARBOXYLIC ACID Reivindicaciones afectadas 1-24, 26 X SEKIHACHI J ET AL: "SYNTHESIS AND CHROMOPHORIC PROPERTIES OF SYMMETRICAL BIS￾HETEROANNELATED DIKETOPIPERAZINES: DIIMIDAZO- AND DIPYRAZOLO-PIPERAZINEDIONES", DYES AND PIGMENTS, ELSEVIER APPLIED SCIENCE PUBLISHERS, BARKING, GB VOL. 32, No. 1, 1 SEPTEMBER 1996 (1996-09-01), PAGES 43-58, XP004033252, ISSN: 0143-7208, DOI: 10.1016 / 0143-7208(96)00009-5 COMPOUNDS 2D-F Reivindicaciones afectadas 24,25 A SEKIHACHI J ET AL: "SYNTHESIS AND CHROMOPHORIC PROPERTIES OF SYMMETRICAL BIS�HETEROANNELATED DIKETOPIPERAZINES: DIIMIDAZO- AND DIPYRAZOLO-PIPERAZINEDIONS", DYES AND PYGMENTS, ELSEVIER APPLIED SCIENCE PUBLISHERS. BARKING, GB, VOL. 32, No. 1, 1 SEPTEMBER 1996 (1996-09-01), PAGES 43-58, XP004033252, ISSN: 0143-7208, DOI: 10.1016 / 0143-7208(96)00009-5 COMPOUNDS ED-F Claims affected 1-23,26 * INHIBITORS OF THE HIV-1 INTEGRASE-LEDGF / P75 INTERAC", BIOORGANIC & MEDICINAL CHEMISTRY, VOL. 21, No. 19, 2 AUGUST 2013 (2013-08-02), PAGES 5963-5972, XP028706282, ISSN: 0968-0896, DOI: 10.1016 / J.BMC.2013.07.047 COMPOUND 17 Affected claims 25 Observations: THIS REPORT WAS BASED ON THE PCT INTERNATIONAL SEARCH REPORT OF THE OFFICE EUROPEAN PATENTS WITH NO WO 2015 / 150449. Report due date: July 10, 2018 140 Y DOHAN EHRENFEST DM ET AL: "CLASSIFICATION OF PLATELET CONCENTRATES: FROM PURE PLATELET�RICH PLASMA (P-PRP) TO LEUCOCYTE- AND PLATELET-RICH FIBRIN (L-PRF)", TRENDS,CHNO BIGY ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, VOL. 27, no. 3, 1 MARCH 2009 (2009-03-01), PAGES 158-167, XPO25958233, ISSN: 0167-7799, DOI: 10.1016 / J.TIBTECH.2008.11.009 [RETRIEVED ON 2009-01-31] ​​THE WHOLE DOCUMENT Claims affected 15 Y US 6 020 196 A (HU CAN B [US] ET AL) 1 FEBRUARY 2000 (2000-02-01) FIGURE 1 Claims affected 15 AND CAROLINA FRANKE MARKARIAN ET AL: "ISOLATION OF ADIPOSE-DERIVED STEM CELLS: A COMPARISON AMONG DIFFERENT METHODS”, BIOTECHNOLOGY LETTERS, VOL. 36, No. 4, 10 DECEMBER 2013 (2013-12-10), PAGES 693-702, XP55155215, ISSN: 0141-5492, DOI: 10.1007 / S10529-013-1425-X- SEE MATERIALS AND METHODS, P. 694 ONWARDS Claims affected 15 A CHOUDHERY MS ET AL: "COMPARISON OF HUMAN MESENCHYMAL STEM CELLS DERIVED FROM ADIPOSE AND CORD TISSUE" CYTOTHERAPY, ISIS MEDICAL MEDIA, OXFORD, GB, VOL. 15 No. 3, MARCH 1, 2013 (2013-03-01) PAGES 330-343, XP002716010, ISSN: 1465-3249, DOI: 10.1016 / J.JCYT. 331 ONWARDS Claims affected 15 A WO 2013 / 144883 A2 (LIPOGEMS INTERNAT SRL [IT]) 3 OCTOBER 2013 (2013-10-03) THE WHOLE DOCUMENT Claims affected 15 X EP 2 361 644 A1 (ASAHI KASEI KURARAY MEDICAL CO [JP]) AUGUST 31, 2011 (2011-08-31) CLAIM 1 Claims affected 1,4 X US 2005 / 205498 A1 (SOWEMIMO-COKER SAMUEL O [US] ET AL) SEPTEMBER 22, 2005 (2005-09-22) THE WHOLE DOCUMENT Reports affected 1-10 X WO 2010 / 122548 A2 (ESTERON AARON [IL]) 28 OCTOBER 2010 (2010-10-28) THE WHOLE DOCUMENT Indications affected 1-10 X WO 2013 / 111130 A1 (ESTAR TECHNOLOGIES LTD [IL]) 1 AUGUST 2013 (2013-08-01) THE WHOLE DOCUMENT Indications affected 1-10 X WO 03 / 095974 A2 (BECTON DICKINSON CO [US]; WALENCIAK MATTHEW [US]; RAINEN LYNNE [US]; G) 20 NOVEMBER 2003 (2003-11-20) CLAIMS 1-61 Reivindicaciones afectadas 1-10 X AHMAD GHORBANI ET AL: "ISOLATION OF ADIPOSE TISSUE MESENCHYMAL STEM CELLS WITHOUT TISSUE DESTRUCTION: A NON-ENZYMATIC METHOD", TISSUE AND CELL, VOL. 46, No. 1, 1 FEBRUARY 2014 (2014-02- 01), PAGES 54-58, XP55152919, ISSN: 0040-8166, DOI: 10.1016 / J.TICE.2013.11.002 THE WHOLE DOCUMENT Reivindicaciones afectadas 15 X KIMURA Y ET AL: "ADIPOSE TISSUE ENGINEERING BASED ON HUMAN PREADIPOCYTES COMBINED WITH GELATIN MICROSPHERES CONTAINING BASIC FIBROBLAST GROWTH FACTOR", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, VOL. 24, No. 14, 1 JUNE 2003 (2003-06-01), PAGES 2513-2521, XP004419996, ISSN: 0142-9612, DOI:10.1016 / S0142-9612(03)00049-8 ABSTRACT SEE ABSTRACT AND MATERIALS AND METHODS Reivindicaciones afectadas 15 X MATSUMOTO D ET AL. "CELL-ASSISTED LIPOTRANSFER: SUPPORTIVE USE OF HUMAN ADIPOSE-DERIVED CELLS FOR SOFT TISSUE AUGMENTATION WITH LIPOINJECTION", TISSUE ENGINEERING, LARCHMONT, NY, US, VOL. 12, No.12, 18 DECEMBER 2006 (2006-12-18) , PAGES 3375-3382, XP002570692, ISSN: 1076-3279, DOI:10.1089 / TEN.2006.12.3375 PAGE 3376, LEFT-HAND COLUMN, PARAGRAPH 4 - RIGHT-HAND COLUMN, PARAGRAPH 1 Reivindicaciones afectadas 15 Observations: THIS REPORT WAS BASED ON THE PCT INTERNATIONAL SEARCH REPORT OF THE OFFICE EUROPEAN PATENT REGISTRATION NO. WO 2016 / 083549. Date of report completion: November 17, 2017 Examiner: JULISSA HILDEGART MONTECER GREEN